Search

Your search keyword '"Hudis, Clifford"' showing total 149 results

Search Constraints

Start Over You searched for: Author "Hudis, Clifford" Remove constraint Author: "Hudis, Clifford" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
149 results on '"Hudis, Clifford"'

Search Results

2. Data from Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients

6. Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

7. Data from Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland

9. Data from Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer

10. Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

11. Supplementary Table 1 from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

13. Supplementary Appendix 1 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

14. Supplementary Tables 1 - 3 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer

15. Supplementary Figure 1 from Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer

16. Supplementary Data from Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients

17. Data from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

18. Supplementary Data from Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland

19. Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease

21. Supplemental Table from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

22. Supplemental Figures from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

23. Data from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

24. Supplemental Figure 5 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

26. Supplementary Tables S1-S3 from The Genomic Landscape of Male Breast Cancers

27. Supplemental Methods from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

28. Supplementary Data from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

29. Supplementary Table 3 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

30. Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

31. Supplementary Tables S11 and S12 from The Genomic Landscape of Male Breast Cancers

32. Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

33. Supplementary Data Files from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

35. Supplemental Figure 2 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

36. Supplementary Figure 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

37. Supplementary Figure 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

39. Supplementary Table 1 from The 6q22.33 Locus and Breast Cancer Susceptibility

40. Supplementary Figures S6-S10 from The Genomic Landscape of Male Breast Cancers

41. Supplementary Table 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

42. Supplementary eTables from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

43. Supplementary Figure 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

44. Supplemental Figure 4 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

45. Supplementary Table 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

46. Data from The 6q22.33 Locus and Breast Cancer Susceptibility

47. Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

48. Supplementary Methods from The Genomic Landscape of Male Breast Cancers

49. Supplementary Table 1 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Catalog

Books, media, physical & digital resources